CD19 and diffuse large B-cell lymphoma: In another study, a 41-year-old female patient with stage IV DLBCL and a 20-year history of SLE was treated with compound CAR T (cCAR T) co-expressing anti-BCMA and anti-CD19 bearing the CD137 co-stimulation domain [66].